^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VCB-1102

    i
    Other names: VCB-1102, VAX-NK/HCC, VCB1102, VCB 1102
    Associations

    News

    Trials
    Company:
    Vaxcell-Bio Therap
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    Natural Killer (NK) Cell Therapy in Locally Advanced HCC (clinicaltrials.gov)
    P2a, N=20, Recruiting, Vaxcell Bio, Co., Ltd. | Trial completion date: Aug 2022 --> May 2024 | Trial primary completion date: Jan 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL10 (Interleukin 10)
    |
    VCB-1102